When expressed on tumor cells or antigen-presenting cells (APCs), PD-L1 engages PD-1 receptors on activated T lymphocytes, delivering inhibitory signals that suppress T cell activation, proliferation, and cytokine production, thereby promoting T cell exhaustion and functional impairment [1]. This evidence concerns the gene CD274 and neoplasm.